

## This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
<b>Infectious disease</b>				
HIV/AIDS	HIV integrase	<p><i>In vitro</i> and canine studies identified a new class of HIV integrase inhibitors that could help treat HIV/AIDS. <i>In vitro</i> testing of dihydronaphthyridinone analogs identified a lead compound that inhibited HIV infection of human T cells with a low nanomolar IC<sub>50</sub> value. In normal dogs, the compound had better oral bioavailability and longer half-life than a previously reported inhibitor of HIV integrase. Next steps could include testing the lead compound in animal models of HIV infection.</p> <p>Merck &amp; Co. Inc. markets the HIV integrase inhibitor Isentress raltegravir to treat HIV/AIDS. GSK1349572, an HIV integrase inhibitor from GlaxoSmithKline plc, Pfizer Inc. and Shionogi &amp; Co. Ltd., is in Phase III testing to treat HIV/AIDS. Elvitegravir (JTK-303; GS 9137), an HIV integrase inhibitor from Japan Tobacco Inc. and Gilead Sciences Inc., is in Phase III testing to treat HIV/AIDS.</p> <p><b>SciBX 4(17); doi:10.1038/scibx.2011.486</b>  <b>Published online April 28, 2011</b></p>	Patent and licensing status undisclosed	<p>Johnson, T.W. <i>et al. J. Med. Chem.</i>; published online March 29, 2011; doi:10.1021/jm200208d</p> <p><b>Contact:</b> Steven P. Tanis, Pfizer Global Research and Development, San Diego, Calif.  e-mail: <a href="mailto:sptanis@sbcglobal.net">sptanis@sbcglobal.net</a>  or <a href="mailto:sptanis@gmail.com">sptanis@gmail.com</a></p> <p><b>Contact:</b> Ted W. Johnson, same affiliation as above  e-mail: <a href="mailto:ted.w.johnson@pfizer.com">ted.w.johnson@pfizer.com</a></p>